NCT05982223 Integrative Medicine in Lymphoma Survivors
| NCT ID | NCT05982223 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bnai Zion Medical Center |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-07-13 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-07-13 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lymphoma is a cancer of the lymph nodes. While some are "silent" and only require follow-up, in cases of aggressive lymphoma, treatment is necessary, and usually includes biological drugs, chemotherapy or both. These drugs often cause significant damage to quality-of-life and various symptoms that do not always go away. Although the treatments are often limited in time and with recovery rates over 60%, most patients are left with a significantly impaired quality-of-life and difficulty in returning to their previous life. Many studies, most of which were conducted in breast cancer survivors, show the place of complementary medicine in the recovery process, both in terms of symptom relief and in improving quality-of-life. Few studies have examined the place of complementary and integrative medicine in lymphoma survivors. The purpose of the present study is to examine the effect of integrative treatments (a combination of conventional and complementary medicine) on quality-of-life of lymphoma survivors, on specific symptoms caused by the disease and its treatment, on economic and social aspects, as well as on the course of the disease. At the hematological unit of Bnai Zion Medical Center, Haifa, Israel, patients with lymphoma who have received chemotherapy, biological treatment or both, and have been defined as recovering by the treating hematologist, will be offered a choice of different types of complementary medicine (acupuncture, herbal medicine, mind-body, movement and touch therapies), emotional treatment (conversations with social worker, spiritual guidance), or both, in addition to the medical and nursing care offered to all survivors. Patients who prefer not to come to the clinic for these treatments will be assigned to the control group and will fill out questionnaires only. The duration of the treatments will be six months and follow-up for another two years. The type of treatments the patient will receive will be chosen in coordination between the integrative team and the patient and according to the symptoms. An assessment will be made on the effect of these treatments on quality-of-life of lymphoma survivors (based on questionnaires), including physical, psycho-spiritual and economic aspects, as well as on the course of the disease.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with a lymphoproliferative disease * Aged 18 years or older * Received chemotherapy, biological treatment or both for treating the lymphoproliferative disease * Defined in remission for less than one year by the haemato-oncologist (maintenance therapy is authorized) * Can respond to questionnaires * Signed informed consent Exclusion Criteria: None
Contact & Investigator
Ilana Levy Yurkovski, MD
PRINCIPAL INVESTIGATOR
Bnai Zion Medical Center
Frequently Asked Questions
Who can join the NCT05982223 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05982223 currently recruiting?
Yes, NCT05982223 is actively recruiting participants. Contact the research team at dana.weizer@b-zion.org.il for enrollment information.
Where is the NCT05982223 trial being conducted?
This trial is being conducted at Haifa, Israel.
Who is sponsoring the NCT05982223 clinical trial?
NCT05982223 is sponsored by Bnai Zion Medical Center. The principal investigator is Ilana Levy Yurkovski, MD at Bnai Zion Medical Center. The trial plans to enroll 90 participants.